Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Complexed PSA in routine diagnosis.

G M Oremek1, N Sapoutzis, F Eden

  • 1Central Laboratory, Hospital of the Johann Wolfgang Goethe-University, Frankfurt/Main, Germany.

Anticancer Research
|June 25, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[The biomarkers BNP and NT-proBNP].

Zentralblatt fur Arbeitsmedizin, Arbeitsschutz und Ergonomie·2023
Same author

Microbial endogenous response to acute inhibitory impact of antibiotics.

Environmental technology·2017
Same author

Genomic evaluation of regional dairy cattle breeds in single-breed and multibreed contexts.

Journal of animal breeding and genetics = Zeitschrift fur Tierzuchtung und Zuchtungsbiologie·2016
Same author

Heater-cooler units: contamination of crucial devices in cardiothoracic surgery.

The Journal of hospital infection·2016
Same author

Correction: Hypoglycemia in Newborn Infants at Risk.

Klinische Padiatrie·2014
Same author

Hypoglycemia in newborn infants at risk.

Klinische Padiatrie·2014
Same journal

Corrigendum.

Anticancer research·2026
Same journal

Geographic Variation in Stage at Diagnosis of Skin Cancer in the United States: A National Cancer Database Analysis.

Anticancer research·2026
Same journal

Anti-tumor Effects of Loureirin A Treatment in Colorectal Cancer Cells <i>via</i> Inhibition of AKT Phosphorylation.

Anticancer research·2026
Same journal

Bayesian Analysis to Refine East Asian Subgroup Estimates in the CLEAR Trial (Lenvatinib Plus Pembrolizumab <i>vs</i>. Sunitinib) for Advanced Renal Cell Carcinoma.

Anticancer research·2026
Same journal

Pulsed Electromagnetic Field Increases Doxorubicin-induced Mitotic Slippage in MDA-MB-231 Breast Cancer Cells.

Anticancer research·2026
Same journal

Geographic Disparities in Socioeconomic Factors and Advanced-stage Presentation in Rectosigmoid Cancer: A National Cancer Database Analysis.

Anticancer research·2026
See all related articles

Complex prostate-specific antigen (cPSA) shows higher sensitivity for early prostate cancer detection than free PSA (fPSA) or total PSA (tPSA). This new tumor marker offers improved specificity, especially in borderline tPSA ranges.

Area of Science:

  • Uro-oncology
  • Biochemical diagnostics
  • Cancer biomarkers

Background:

  • Prostatic tumor tissue produces a more complex form of PSA (cPSA) than free PSA (fPSA).
  • cPSA is hypothesized to be more sensitive than the ratio of fPSA and tPSA for early prostate cancer detection.
  • Evaluating cPSA's diagnostic value in early malignant prostatic tumor detection is crucial.

Purpose of the Study:

  • To evaluate the diagnostic value of cPSA in early prostate cancer detection.
  • To compare the efficacy of cPSA with routinely used fPSA and tPSA tests.
  • To assess cPSA's specificity and sensitivity in various tPSA concentration ranges.

Main Methods:

  • A cohort of 100 patients with urological symptoms underwent evaluation using cPSA, fPSA, and tPSA tests.

Related Experiment Videos

  • Biopsy and histological examination were performed for all patients.
  • Laboratory results were compared with histological findings using immunological and electrochemiluminescence methods.

    • Main Results:

    • Histological examination confirmed 59 malignant and 41 benign prostatic processes.
    • With a cPSA cut-off of 2.3 ng/ml and tPSA range of 2.0-4.0 ng/ml, tumor sensitivity was 92%.
    • cPSA detected malignancy earlier than tPSA, even within the normal tPSA range (2.0-4.0 ng/ml), and provided more specific results (71% improvement) than the PSA ratio.
    • cPSA demonstrated superior stability during transport and storage compared to fPSA.

    Conclusions:

    • The novel tumor marker cPSA exhibits enhanced specificity in the tPSA concentration range of 2.0-4.0 ng/ml and the grey zone of 4.0-10 ng/ml.
    • cPSA aids in the earlier detection of malignant prostatic tumors.
    • cPSA offers a more stable and reliable alternative to fPSA for diagnostic purposes.